# Identification and validation of integrated stress-response-related genes as biomarkers for age-related macular degeneration

**Authors:** Jingyi Niu, Ling Jin, Yijun Hu, Yiting Wang, Xiaoning Hao, Wenwen Geng, Ruirui Ma

PMC · DOI: 10.3389/fmolb.2025.1583237 · Frontiers in Molecular Biosciences · 2025-07-16

## TL;DR

This study identifies SLFN11 and GRIN1 as potential biomarkers for age-related macular degeneration, using bioinformatics and validation techniques.

## Contribution

The study introduces a novel approach combining ISR-related genes and transcriptomic data to identify and validate AMD biomarkers.

## Key findings

- SLFN11 and GRIN1 were identified as common biomarkers for AMD with good diagnostic predictive abilities (AUC > 0.7).
- SLFN11 and GRIN1 were enriched in pathways like proteasome and lysosome, and showed higher expression in AMD patients.
- RT-qPCR validation confirmed elevated SLFN11 and GRIN1 expression in AMD patients compared to controls.

## Abstract

Age-related macular degeneration (AMD) is a prevalent ocular condition associated with aging, serving as a significant contributor to vision loss among middle-aged and older individuals. Studies have shown that AMD and integrated stress response (ISR) are associated with oxidative stress, but no specific molecular mechanisms have been identified. Therefore, this study aimed to identify potential biomarkers for AMD through bioinformatics analysis based on the transcriptome database and integrated stress response related genes (ISR-RGs).

Transcriptomic data GSE76237, GSE247168, and ISR-RGs were sourced from public databases and related literature. The biomarkers associated with AMD were identified by differentially expressed gene (DEG) analysis, intersection of common DEGs, and ISR-RGs machine algorithm. After that, nomograms, GSEA, and immune infiltration analysis were performed for the biomarkers. The effects of transcription factors (TFs) and miRNAs on biomarkers were then explored by constructing a TF-biomarker–miRNA regulatory network. In addition, potential effective drugs of the biomarkers were explored by constructing a biomarker–effective drug interaction network. Finally, we verified the gene expression of the biomarkers by RT-qPCR.

We obtained 2,567 and 1,454 DEGs in GSE76237 and GSE247168, respectively. The up- and downregulated genes shared in both datasets were intersected with ISR-RGs taken to obtain eight candidate genes. SLFN11 and GRIN1 were identified as common biomarkers for AMD. An analysis of the nomogram model of biomarkers revealed good diagnostic predictive abilities (AUC > 0.7). SLFN11 and GRIN1 were mainly enriched in pathways such as proteasome, lysosome, and neuroactive ligand receptor interaction. In addition, the disease group’s monocyte expression was significantly higher than that of the control group in GSE76237 (p < 0.01). We obtained thirteen relevant miRNAs and 27 TFs by prediction, with three shared TFs, and seventeen potentially effective drugs were predicted. RT-qPCR validation showed in AMD patients, and SLFN11 and GRIN1 expression was significantly higher than controls (p < 0.05). Only SLFN11 expression was consistent with the bioinformatics analysis.

SLFN11 and GRIN1 were identified as AMD biomarkers, exhibiting robust diagnostic performance and providing new insights into the condition.

## Linked entities

- **Genes:** SLFN11 (schlafen family member 11) [NCBI Gene 91607], GRIN1 (glutamate ionotropic receptor NMDA type subunit 1) [NCBI Gene 2902]
- **Diseases:** age-related macular degeneration (MONDO:0005150), AMD (MONDO:0005150)

## Full-text entities

- **Genes:** AKAP6 (A-kinase anchoring protein 6) [NCBI Gene 9472] {aka ADAP100, ADAP6, AKAP100, PRKA6, mAKAP}, GRIK3 (glutamate ionotropic receptor kainate type subunit 3) [NCBI Gene 2899] {aka EAA5, GLR7, GLUR7, GluK3, GluR7a}, EIF2AK2 (eukaryotic translation initiation factor 2 alpha kinase 2) [NCBI Gene 5610] {aka PKR, PPP1R83, PRKR}, Cst7 (cystatin F (leukocystatin)) [NCBI Gene 13011] {aka Cmap}, F3 (coagulation factor III, tissue factor) [NCBI Gene 2152] {aka CD142, TF, TFA}, SLFN11 (schlafen family member 11) [NCBI Gene 91607] {aka SLFN8/9}, Grin1 (glutamate receptor, ionotropic, NMDA1 (zeta 1)) [NCBI Gene 14810] {aka GluN1, GluRdelta1, GluRzeta1, M100174, NMD-R1, NMDAR1}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) [NCBI Gene 2146] {aka ENX-1, ENX1, EZH2b, KMT6, KMT6A, WVS}, FAM111A (FAM111 trypsin like peptidase A) [NCBI Gene 63901] {aka GCLEB, KCS2}, BDNF (brain derived neurotrophic factor) [NCBI Gene 627] {aka ANON2, BULN2}, EIF2AK1 (eukaryotic translation initiation factor 2 alpha kinase 1) [NCBI Gene 27102] {aka HCR, HRI, hHRI}, GRIA1 (glutamate ionotropic receptor AMPA type subunit 1) [NCBI Gene 2890] {aka GLUH1, GLUR1, GLURA, GluA1, HBGR1, MRD67}, ZNF394 (zinc finger protein 394) [NCBI Gene 84124] {aka ZKSCAN14, ZSCAN46}, EIF2AK3 (eukaryotic translation initiation factor 2 alpha kinase 3) [NCBI Gene 9451] {aka PEK, PERK, WRS}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, MIR607 (microRNA 607) [NCBI Gene 693192] {aka MIRN607, hsa-mir-607}, RIC3 (RIC3 acetylcholine receptor chaperone) [NCBI Gene 79608] {aka AYST720, PRO1385, RIC-3}, PKD2 (polycystin 2, transient receptor potential cation channel) [NCBI Gene 5311] {aka APKD2, PC2, PKD4, Pc-2, TRPP2}, EIF2A (eukaryotic translation initiation factor 2A) [NCBI Gene 83939] {aka CDA02, EIF-2A, MST089, MSTP004, MSTP089}, EIF2AK4 (eukaryotic translation initiation factor 2 alpha kinase 4) [NCBI Gene 440275] {aka GCN2, PVOD2}, Parp1 (poly (ADP-ribose) polymerase family, member 1) [NCBI Gene 11545] {aka 5830444G22Rik, ARTD1, Adprp, Adprt1, PARP, PPOL}, SUZ12 (SUZ12 polycomb repressive complex 2 subunit) [NCBI Gene 23512] {aka CHET9, IMMAS, JJAZ1}, STOX1 (storkhead box 1) [NCBI Gene 219736] {aka C10orf24}, Ddit4 (DNA-damage-inducible transcript 4) [NCBI Gene 74747] {aka 5830413E08Rik, REDD1, Rtp801, dig2}, ATF4 (activating transcription factor 4) [NCBI Gene 468] {aka CREB-2, CREB2, TAXREB67, TXREB}, Psen1 (presenilin 1) [NCBI Gene 19164] {aka Ad3h, PS-1, PS1, S182}, GRIN1 (glutamate ionotropic receptor NMDA type subunit 1) [NCBI Gene 2902] {aka DEE101, GluN1, MRD8, NDHMSD, NDHMSR, NMD-R1}, SGPP2 (sphingosine-1-phosphate phosphatase 2) [NCBI Gene 130367] {aka SPP2, SPPase2}
- **Diseases:** inflammation (MESH:D007249), cancer (MESH:D009369), AMD (MESH:D008268), Down's syndrome (MESH:D004314), metabolic diseases (MESH:D008659), amphetamine addiction (MESH:D019969), Age-Related Eye Disease (MESH:D005128), neurological conditions (MESH:D019636), deterioration of retinal function (MESH:D012173), diabetic retinopathy (MESH:D003930), neuroinflammatory (MESH:D000090862), GRIN disorders (MESH:D009358), type 2 diabetes (MESH:D003924), AECOPD (MESH:D029424), graft versus host disease (MESH:D006086), heme deficiency (MESH:D046351), breast cancer (MESH:D001943), Parkinson's disease (MESH:D010300), Alzheimer's disease (MESH:D000544), diseases of the nervous system (MESH:D009422), neurological disorders (MESH:D009461), chronic (MESH:D002908), retinal degeneration (MESH:D012162), peripheral neuropathies (MESH:D010523), atherogenesis (MESH:D050197), cocaine addiction (MESH:D019970), ACLF (MESH:D065290), CVI (MESH:D014786), glioma (MESH:D005910), ovarian, lung, and colorectal cancers (MESH:D010051), subretinal neovascularization (MESH:D006949), viral infection (MESH:D014777), drusen (MESH:D015593), RPE dysfunction (MESH:C536309), anxiety (MESH:D001007), depression (MESH:D003866), GA (MESH:D057092), epilepsy (MESH:D004827), non-small-cell lung cancer (MESH:D002289), basal cell carcinoma (MESH:D002280), ISR (MESH:D000079225), muscular hypotonia (MESH:D009123), pulmonary diseases (MESH:D008171), NEO (MESH:D016510), sleep problems (MESH:D012893), ASD (MESH:D000067877), autoimmune and inflammatory diseases (MESH:D001327), photoreceptor damage (MESH:D020263), intellectual disability (MESH:D008607), neurodevelopmental disorders (MESH:D002658), motor dysfunction (MESH:D000068079), legal blindness (MESH:D001766), nicotine addiction (MESH:D014029)
- **Chemicals:** alkylating (-), TCA (MESH:D014233), sphingolipid (MESH:D013107), cupric oxide (MESH:C030973), zeaxanthin (MESH:D065146), oxygen (MESH:D010100), cholesterol (MESH:D002784), zinc oxide (MESH:D015034), NaIO3 (MESH:C032285), lutein (MESH:D014975), gemcitabine (MESH:D000093542), TRIzol (MESH:C411644), irinotecan (MESH:D000077146), cisplatin (MESH:D002945), lipid (MESH:D008055), LPS (MESH:D008070), etoposide (MESH:D005047), TSA (MESH:C012589)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606], Human immunodeficiency virus 1 (no rank) [taxon 11676], Rattus norvegicus (brown rat, species) [taxon 10116]
- **Mutations:** rs6293, rs534131, rs2195450
- **Cell lines:** BV2 — Mus musculus (Mouse), Transformed cell line (CVCL_0182), RPE — Homo sapiens (Human), Spontaneously immortalized cell line (CVCL_IQ82)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12307159/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12307159/full.md

## References

92 references — full list in the complete paper: https://tomesphere.com/paper/PMC12307159/full.md

---
Source: https://tomesphere.com/paper/PMC12307159